Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas

Area of Science:

• Oncology
• Cancer Biology
• Translational Research

Background:

• Stem cells are increasingly recognized as key drivers of resistance to anticancer therapies.
• Understanding the role of stem cell populations in treatment response is crucial for improving breast cancer outcomes.

Purpose of the Study:

• To investigate the association between stem cell markers and tumor regression in breast carcinomas following neoadjuvant therapy.
• To identify potential stem cell-based predictors of treatment response in breast cancer.

Main Methods:

• Analysis of 92 breast carcinoma patients undergoing neoadjuvant therapy.
• Tumor regression assessment using the Miller and Payne grading system.
• Immunohistochemical detection of stem cell markers (CD44, CD24, CD29, CD133, ID4, ALDH1) in tumor tissues.

Main Results:

• High-grade tumors and HER2-positive status were more frequent in patients with near-complete/complete response.
• Increased expression of CD44 and CD24 was significantly associated with poor response to therapy (P = 0.027 and P = 0.001, respectively).
• CD29 expression was reduced in residual tumors of patients with a near-complete/complete response.

Conclusions:

• Elevated CD44 and CD24 expression may serve as predictive biomarkers for non-response to neoadjuvant therapy in breast cancer.
• Targeting CD44 and CD24 pathways could be a potential strategy to overcome treatment resistance in breast carcinomas.